Migraine affects approximately 44 million people in the United States and one billion people globally. The personal, professional, and financial costs through lost productivity and quality of life are immense. Despite its prevalence and impact on individuals, families, and society, migraine is under-recognized, underdiagnosed, and undertreated.

Interviews with patients integrated into the educational activities uncovered chronic migraine episodes that sidelined careers, interrupted social engagements, and impacted individuals’ ability to function. Patients look to their health care providers to share information, insights, and experience as part of shared decision-making to find multimodal treatment strategies that will curtail the disability of migraine.

New agents targeting the calcitonin gene-related peptide (CGRP) pathway have shown great promise and have led to excitement within the migraine community. Our goal for the Migraine Digital Hub is to provide educational activities, clinical information, resources, and assessment  for the diagnosis and management of migraine. Our end goal is to improve the lives of individuals with migraine.

Getting Ahead of Migraine: Integrating Preventive Strategies Into Migraine Care

Migraine is a debilitating condition with profound effects on individuals’ quality of life, accounting for five to nine million primary care visits each year. It is estimated that 38% of sufferers could benefit from preventative treatment, but few are currently using them nor are their healthcare providers discussing these options with them. Consequently, there is great interest in emerging data about calcitonin gene-related peptide (CGRP) agents as novel options for migraine prevention and the benefits they may provide to patients.

Participate Now!

The International Classification of Headache Disorders, 3rd Edition

 

Read Now!

The Pathophysiology of Migraine: Implications for Clinical Management

Charles A. Lancet Neurol. 2018;17(2):174-182.

 

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial

Skljarevski V, et al. JAMA Neurol. 2018;75(2):187-193.

 

A Controlled Trial of Erenumab for Episodic Migraine

Goadsby P, et al. N Engl J Med. 2017;377:2123-32.

 

Fremanezumab for the Preventive Treatment of Chronic Migraine

Silberstein SD, et al. N Engl J Med. 2017:377(22):2113-2122.

 

Migraine

Charles A. N Engl J Med. 2017;377(6):553-561.

 

Impact of Migraine on the Family: Perspectives of People with Migraine and Their Spouse/Domestic Partner in the CaMEO Study

Buse DC, et al. Mayo Clin Proc. 2016 Apr 25. [Epub ahead of print]

 

Migraine Aura: New Ideas About Cause, Classification, and Clinical Significance.

Charles A, Hansen JM. Curr Opin Neurol.2015;28(3):255-260.

American Migraine Foundation – Website